Safety of repeated cell‑free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer

Maeda,Osamu; Ando,Takafumi; Ishiguro,Kazuhiro; Watanabe,Osamu; Miyahara,Ryoji; Nakamura,Masanao; Funasaka,Kohei; Kazuhiro,Furukawa; Ando,Yuichi; Goto,Hidemi

doi:10.3892/mco.2014.335

November-December 2014 Volume 2 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-December 2014 Volume 2 Issue 6

Full Size Image

Article

Safety of repeated cell‑free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer

Authors:
- Osamu Maeda
- Takafumi Ando
- Kazuhiro Ishiguro
- Osamu Watanabe
- Ryoji Miyahara
- Masanao Nakamura
- Kohei Funasaka
- Furukawa Kazuhiro
- Yuichi Ando
- Hidemi Goto
View Affiliations / Copyright

Affiliations: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi 466‑8550, Japan, Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan
Pages: 1103-1106
|
Published online on: July 4, 2014

https://doi.org/10.3892/mco.2014.335
Expand metrics +

Abstract

Malignant ascites due to peritoneal metastasis is one of the major problems caused by advanced gastrointestinal cancer. Although drainage of a large amount of ascitic fluid improves symptoms such as abdominal fullness, it may lead to protein loss and renal dysfunction. Cell‑free and concentrated ascites reinfusion therapy (CART) may help avoid such complications due to paracentesis. The purpose of this study was to evaluate the safety of CART. We performed a total of 51 sessions of CART in 5 patients, 4 of whom had gastric cancer and 1 appendiceal cancer. We retrospectively evaluated laboratory data immediately prior to CART, on the following day, 1 week later and 2 weeks later. We also measured the amount of total protein and albumin in collected and concentrated ascites. The mean amount of collected ascites was 4,007 ml. All the patients exhibited improvement of symptoms such as abdominal fullness. Four patients developed fever (>38˚C) immediately after reinfusion of the concentrated ascites and 3 of these patients required corticosteroid administration. The mean total protein and albumin in the collected ascites were 122 and 64 g, respectively, and those in the concentrated ascites 75 and 39 g, respectively. The serum levels of total protein, albumin and creatinine after CART were almost identical to those prior to CART. Blood hemoglobin concentration was significantly decreased 1 day after CART and returned to baseline levels in 1‑2 weeks. CART does not cause renal dysfunction and does not decrease serum albumin; therefore, repeated CART is safe and may be used to improve the symptoms of malignant ascites from gastrointestinal cancer.

View Figures

View References

1	Chung M and Kozuch P: Treatment of malignant ascites. Curr Treat Options Oncol. 9:215–233. 2008. View Article : Google Scholar
2	Inoue N, Yamazaki Z, Oda T, Sugiura M and Wada T: Treatment of intractable ascites by continuous reinfusion of the sterilized, cell-free and concentrated ascitic fluid. Trans Am Soc Artif Intern Organs. 23:699–702. 1977. View Article : Google Scholar : PubMed/NCBI
3	Japanese CART Study Group. Matsusaki K, Ohta K, Yoshizawa A and Gyoda Y: Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int J Clin Oncol. 16:395–400. 2011. View Article : Google Scholar : PubMed/NCBI
4	Nakamoto S, Britton RC and Kolff WJ: Ultrafiltration of ascites. Trans Am Soc Artif Intern Organs. 6:15–21. 1960.
5	Takahashi K, Shibukawa T, Moriyama M and Kitao M: Changes in biochemical data in ascites and serum before and after the treatment of intractable ascites for patients with terminal gynecologic tumor: re-infusion of cell-free and concentrated ascitic fluid. Nihon Gan Chiryo Gakkai Shi. 20:2097–2103. 1985.
6	Maeda A, Takeda K, Tsuruya K, et al: A case of cell-free and concentrated ascites reinfusion therapy effective for refractory ascites in spontaneous bacterial peritonitis in a renal transplant patient. Case Rep Nephrol Urol. 2:138–144. 2012. View Article : Google Scholar
7	Britton RC: A new technique for rapid control of cirrhotic ascites. Arch Surg. 83:364–369. 1961. View Article : Google Scholar
8	Ueda T, Maehara M, Takahashi Y, et al: Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer. Anticancer Res. 32:2353–2357. 2012.PubMed/NCBI
9	Kitao M, Takahashi K and Iwaka O: Treatment of intractable ascites at the terminal stage of ovarian carcinoma - reinfusion of the cell-free, concentrated ascitic fluid. Nihon Sanka Fujinka Gakkai Zasshi. 35:1668–1671. 1983.(In Japanese).
10	Graziotto A, Rossaro L, Inturri P and Salvagnini M: Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Dig Dis Sci. 42:1708–1714. 1997. View Article : Google Scholar : PubMed/NCBI
11	Katoh S, Tatsukawa H, Kondoh M, Inoue M, Ida K and Miyagawa F: Prevention of the febrile reaction occurring on reinfusion of cell-free and concentrated autogenous ascites. Jpn J Med. 30:311–317. 1991. View Article : Google Scholar : PubMed/NCBI
12	Orimi S, Mizuno K, Narahara M, Umakosi H, Kaihara M and Hashimoto M: A study of appropriate flow rate settings for cell-free and concentrated ascites reinfusion therapy and change of cytokine concentrations in ascites. Ther Apher Dial. 15:411–414. 2011.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Safety of repeated cell‑free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer

This article is mentioned in:

Abstract

Figure 1

Related Articles